Scopus Biopharma Inc. (SCPS): Price and Financial Metrics
SCPS Price/Volume Stats
| Current price | $0.00 | 52-week high | $0.11 |
| Prev. close | $0.00 | 52-week low | $0.00 |
| Day low | $0.00 | Volume | 943 |
| Day high | $0.00 | Avg. volume | 6,433 |
| 50-day MA | $0.02 | Dividend yield | N/A |
| 200-day MA | $0.04 | Market Cap | 46.29K |
SCPS Stock Price Chart Interactive Chart >
Scopus Biopharma Inc. (SCPS) Company Bio
Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.
Latest SCPS News From Around the Web
Below are the latest news stories about SCOPUS BIOPHARMA INC that investors may wish to consider to help them evaluate SCPS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off the final trading day this week with a look at the biggest pre-market stock movers to watch for Friday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday! |
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of CancerNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer (“SITC”). SITC is being held from November 8-12, 2022 at the Boston C |
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder ValueWarrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet Duet Being Positioned to Go Public in 2023 NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, a |
SCPS Price Returns
| 1-mo | 0.00% |
| 3-mo | 0.00% |
| 6-mo | 0.00% |
| 1-year | 0.00% |
| 3-year | 0.00% |
| 5-year | N/A |
| YTD | 0.00% |
| 2023 | -55.79% |
| 2022 | -94.04% |
| 2021 | -88.98% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...